NexgenRx Management
Management criteria checks 2/4
NexgenRx's CEO is Ron Loucks, appointed in Mar 2003, has a tenure of 21.17 years. total yearly compensation is CA$313.34K, comprised of 75% salary and 25% bonuses, including company stock and options. directly owns 10.34% of the company’s shares, worth CA$1.61M. The average tenure of the management team and the board of directors is 7 years and 12.5 years respectively.
Key information
Ron Loucks
Chief executive officer
CA$313.3k
Total compensation
| CEO salary percentage | 75.0% |
| CEO tenure | 21.2yrs |
| CEO ownership | 10.3% |
| Management average tenure | 7yrs |
| Board average tenure | 12.5yrs |
Recent management updates
Recent updates
NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues
Mar 14
Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today
Mar 07Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?
Oct 18Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?
Nov 30What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You
Aug 24Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up
Jun 03NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 19
How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CA$313k | CA$235k | -CA$332k |
| Sep 30 2023 | n/a | n/a | -CA$310k |
| Jun 30 2023 | n/a | n/a | -CA$244k |
| Mar 31 2023 | n/a | n/a | -CA$172k |
| Dec 31 2022 | CA$287k | CA$235k | -CA$22k |
| Sep 30 2022 | n/a | n/a | CA$3m |
| Jun 30 2022 | n/a | n/a | CA$4m |
| Mar 31 2022 | n/a | n/a | CA$4m |
| Dec 31 2021 | CA$230k | CA$215k | CA$4m |
| Sep 30 2021 | n/a | n/a | CA$2m |
| Jun 30 2021 | n/a | n/a | CA$2m |
| Mar 31 2021 | n/a | n/a | CA$2m |
| Dec 31 2020 | CA$153k | CA$140k | CA$2m |
| Sep 30 2020 | n/a | n/a | CA$1m |
| Jun 30 2020 | n/a | n/a | CA$483k |
| Mar 31 2020 | n/a | n/a | -CA$31k |
| Dec 31 2019 | CA$181k | CA$165k | -CA$208k |
| Sep 30 2019 | n/a | n/a | CA$38k |
| Jun 30 2019 | n/a | n/a | -CA$147k |
| Mar 31 2019 | n/a | n/a | -CA$438k |
| Dec 31 2018 | CA$181k | CA$165k | -CA$697k |
| Sep 30 2018 | n/a | n/a | -CA$1m |
| Jun 30 2018 | n/a | n/a | -CA$1m |
| Mar 31 2018 | n/a | n/a | -CA$793k |
| Dec 31 2017 | CA$181k | CA$165k | -CA$626k |
Compensation vs Market: Ron's total compensation ($USD227.71K) is above average for companies of similar size in the Canadian market ($USD174.31K).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
CEO
Ron Loucks (73 yo)
21.2yrs
Tenure
CA$313,342
Compensation
Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.2yrs | CA$313.34k | 10.34% CA$ 1.6m | |
| Chief Financial Officer | 7yrs | CA$60.00k | no data | |
| Senior Vice President of Pharma & Payor Partners | no data | CA$169.40k | no data | |
| Senior Vice President of Administration | no data | no data | no data | |
| Lead Human Resources | no data | no data | no data | |
| Company Secretary | 2.9yrs | no data | no data | |
| Financial Controller | no data | no data | no data |
7.0yrs
Average Tenure
Experienced Management: NXG's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.2yrs | CA$313.34k | 10.34% CA$ 1.6m | |
| Independent Chairman | 18.2yrs | CA$30.00k | 0.88% CA$ 137.6k | |
| Independent Director | 6.9yrs | CA$22.50k | 5.01% CA$ 782.2k | |
| Independent Director | 5.8yrs | CA$20.00k | 0.14% CA$ 22.0k |
12.5yrs
Average Tenure
Experienced Board: NXG's board of directors are seasoned and experienced ( 12.5 years average tenure).